Drug interactions and safety profiles with concomitant use of caspofungin and calcineurin inhibitors in allogeneic haematopoietic cell transplantation.
Br J Clin Pharmacol
; 83(9): 2000-2007, 2017 Sep.
Article
en En
| MEDLINE
| ID: mdl-28407449
ABSTRACT
AIM:
Small-scale clinical studies have reported on drug interactions between caspofungin (CPFG) and calcineurin inhibitors in healthy subjects; however, little is known about these interactions in allogeneic haematopoietic cell transplantation (allo-HCT) patients.METHODS:
We retrospectively assessed the drug interactions and safety profiles in allo-HCT recipients treated concomitantly with CPFG and calcineurin inhibitors.RESULTS:
Ninety-one consecutive cases were evaluated. There were no statistically significant differences in the plasma concentration/dose (C/D) ratios of tacrolimus (TAC) in 34 patients before and after co-administration with CPFG (median 575.6-672.4, P = 0.200). In contrast, the median C/D ratio of cyclosporin A (CsA) in 16 patients was significantly elevated after co-administration with CPFG (median 62.8-74.9, P = 0.016). There were no serious adverse effects on liver or renal function associated with the therapy.CONCLUSIONS:
Our data show that CPFG did not affect the pharmacokinetics of TAC and that it could mildly increase CsA blood concentrations in allo-HCT patients.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Tacrolimus
/
Ciclosporina
/
Trasplante de Células Madre Hematopoyéticas
/
Interacciones Farmacológicas
/
Quimioterapia Combinada
/
Equinocandinas
/
Lipopéptidos
Tipo de estudio:
Observational_studies
/
Risk_factors_studies
Límite:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Br J Clin Pharmacol
Año:
2017
Tipo del documento:
Article
País de afiliación:
Japón